ClinicalTrials.gg
RecruitingNCT06546085Updated Jan 23, 2026

Extracellular Vesicles, Insulin Action, and Exercise

An interventional study of Exercise in Type 2 Diabetes and Obesity, sponsored by Rutgers, The State University of New Jersey. Recruiting at 3 sites in United States. Open to participants aged 30 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.

Planned enrollment
4th of 12
60 · median 54
Started
2025
with 1 other
No phase
11 of 12
4 open now
Registered
7th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 with no phase, and was the 7th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

Extracellular vesicles (EVs) play a role in obesity-induced insulin resistance and likely impact the development of cardiovascular disease. However, little is known on how EVs affect vascular insulin action in people. The purpose of this study is to understand how EVs play a role in type 2 diabetes related cardiovascular disease. This research will also study if exercise can change how EVs impact blood flow and metabolic health. This study will contribute to designing precision medicine to treat/prevent cardiovascular disease in type 2 diabetes.

Read the detailed description

Insulin resistance is a key underlying factor promoting hyperglycemia and hypertension in people with type 2 diabetes (T2D), who have a 3-fold greater cardiovascular disease (CVD) risk when compared with healthy controls. Despite several therapeutic approaches that favor insulin sensitivity through a variety of purported mechanisms (e.g. weight loss, incretins, AMPK activation, reduction in bioactive lipids: DAG/ceramides, etc.), long-term progression of glucose deterioration occurs. This suggests adjunctive targets may be important to prevent/reverse T2D. Studies show that extracellular vesicles (EVs) obtained from plasma are involved in obesity-induced insulin resistance at levels of adipocytes, muscle, and liver. However, little is known how plasma EVs affect vascular insulin action in humans. This is of clinical relevance as EVs enhance the Framingham Risk Score, suggesting EVs are a unique factor promoting CVD. This proposal will fill this knowledge gap by conducting a translational study in 3 distinct groups of people separated by obesity and T2D. The investigators hypothesize that 1) insulin will promote EV uptake and modify insulin signaling in endothelial cells, 2) EVs from adults with T2D will impair vessel reactivity compared to controls; 3) insulin will alter circulating EV insulin signaling and cargo, and 4) exercise training will change EV uptake and cargo as well as EV mediated vascular reactivity to insulin as well as relate to improved vascular function in humans.

03

Conditions studied

  • Type 2 Diabetes
  • Obesity
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 30 - 80 years old.
  • \<5.7% and fasting glucose \<100mg/dl to be considered NGT
  • T2D diagnosis or confirmation HbA1c ≥6.5% and fasting glucose ≥126 mg/dl
  • Prescribed metformin, GLP-1 agonists (oral/injectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors ≥6 year.
  • Has a of 20-24.99 or 25.0-45 kg/m2.
  • Not diagnosed with Type 1 diabetes.
  • Not currently engaged in >150 min/wk of exercise.

Exclusion criteria

Exclusion Criteria:

  • Participants with morbid obesity ( >45 kg/m2) and underweight patients (BMI: ≤18 kg/m2).
  • Intolerance to insulin
  • Evidence of type 1 diabetes and diabetics requiring insulin therapy.
  • Participants who have not been weight stable (≥2 kg weight change in past 6 months)
  • Participants who have been recently active in past 6 months via health screening questions (≥150 min of moderate/high intensity exercise)
  • T2D with ≥10.0%
  • Participants who are smokers or who have quit smoking ≤2 years ago
  • Participants prescribed metformin, GLP-1 agonists (oral/injectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors within 6 year.
  • Hypertriglyceridemic (≥400 mg/dl) and hypercholesterolemic (≥260 mg/dl) participants as determined from LabCorp samples.
  • Kidney dysfunction as determined from LabCorp biochemical outcomes (e.g. creatinine (≥1.0 mg/dl), (≤59 ml/min/1.73), BUN (≥24 mg/dl) as derived from comprehensive metabolic panels).
  • Hypertensive (≥160/100 mmHg) at time of screening.
  • Abnormal liver function (reflective from comprehensive panel liver enzymes Alk (≥121 IU/L), (≥40 IU/L) and ALT (≥32 IU/L) via LabCorp).
  • History of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.
  • Pregnant (as evidenced by positive pregnancy test) or nursing women
  • Participants with to participation in an exercise training program
  • Known to perflutren (contained in Definity).
  • Anemic as confirmed by hematocrit (HCT) (women ≤36%, Men ≤38%) at time of screening.
  • Suggested infections at time of screening as confirmed by WBC (≥10.8 x10E3/uL) and/or (≥450 x10E3/uL).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Lean with Normal Glucose Tolerance

    Participants will not receive the study intervention and will be healthy controls.

  • Experimental
    Obesity with Normal Glucose Tolerance

    Participants with obesity and normal glucose tolerance will participate in 3 supervised exercise training sessions at 85% VO2max that expends \~400 kcal for 16 weeks.

    Behavioral: Exercise

  • Experimental
    Obesity with Type 2 Diabetes

    Participants with obesity and type 2 diabetes will participate in 3 supervised exercise training sessions at 85% VO2max that expends \~400 kcal for 16 weeks.

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.

06

What researchers measure

Primary outcomes

  1. Change in Extracellular Vesicles during insulin infusion

    Extracellular vesicles (CD41 -CD31+, CD45, Tx, CD31, CD105) will be isolated from plasma before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

Secondary outcomes

  1. Change in Metabolic Insulin Sensitivity by the Isoglycemic Clamp

    Measure of glucose metabolism determined by the glucose infusion during the last 30 minutes of the 150 clamp procedure.

    Time frame: From enrollment to the end of treatment at 16 weeks.

  2. Change in Contrast Enhanced Ultrasound

    Measure of microvascular blood flow before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

  3. Change in Flow Mediated Dilation of the brachial artery

    Measure of blood flow using ultrasound before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

  4. Change in Pulse Wave Velocity

    Measure of arterial stiffness using pulse waves at the carotid and femoral arteries before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

  5. Change in Augmentation Index

    Measure of aortic pressure waveforms before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

  6. Change in Post Ischemic Flow Velocity in the brachial artery

    Measure of blood flow using ultrasound before and during insulin stimulation.

    Time frame: From enrollment to the end of treatment at 16 weeks.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Zhang M, Wang L, Chen Z. Research progress of extracellular vesicles in type 2 diabetes and its complications. Diabet Med. 2022 Sep;39(9):e14865. doi: 10.1111/dme.14865. Epub 2022 May 20. PubMed 35509124 ↗
  • Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol. 2009 Aug 11;54(7):601-8. doi: 10.1016/j.jacc.2009.05.022. PubMed 19660689 ↗
  • Ragland TJ, Heiston EM, Ballantyne A, Stewart NR, La Salvia S, Musante L, Luse MA, Isakson BE, Erdbrugger U, Malin SK. Extracellular vesicles and insulin-mediated vascular function in metabolic syndrome. Physiol Rep. 2023 Jan;11(1):e15530. doi: 10.14814/phy2.15530. PubMed 36597186 ↗
  • Heiston EM, Ballantyne A, Stewart NR, La Salvia S, Musante L, Lanningan J, Erdbrugger U, Malin SK. Insulin infusion decreases medium-sized extracellular vesicles in adults with metabolic syndrome. Am J Physiol Endocrinol Metab. 2022 Oct 1;323(4):E378-E388. doi: 10.1152/ajpendo.00022.2022. Epub 2022 Jul 20. PubMed 35858245 ↗
  • Heiston EM, Ballantyne A, La Salvia S, Musante L, Erdbrugger U, Malin SK. Acute exercise decreases insulin-stimulated extracellular vesicles in conjunction with augmentation index in adults with obesity. J Physiol. 2023 Nov;601(22):5033-5050. doi: 10.1113/JP282274. Epub 2022 Feb 16. PubMed 35081660 ↗
  • Eichner NZM, Gilbertson NM, Heiston EM, Musante L, LA Salvia S, Weltman A, Erdbrugger U, Malin SK. Interval Exercise Lowers Circulating CD105 Extracellular Vesicles in Prediabetes. Med Sci Sports Exerc. 2020 Mar;52(3):729-735. doi: 10.1249/MSS.0000000000002185. PubMed 31609300 ↗
  • Hallmark R, Patrie JT, Liu Z, Gaesser GA, Barrett EJ, Weltman A. The effect of exercise intensity on endothelial function in physically inactive lean and obese adults. PLoS One. 2014 Jan 20;9(1):e85450. doi: 10.1371/journal.pone.0085450. eCollection 2014. PubMed 24465565 ↗
  • Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996 Jun 1;97(11):2601-10. doi: 10.1172/JCI118709. PubMed 8647954 ↗
  • Solomon TP, Malin SK, Karstoft K, Haus JM, Kirwan JP. The influence of hyperglycemia on the therapeutic effect of exercise on glycemic control in patients with type 2 diabetes mellitus. JAMA Intern Med. 2013 Oct 28;173(19):1834-6. doi: 10.1001/jamainternmed.2013.7783. No abstract available. PubMed 23817567 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2029, 47 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 47 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 9, 2024
StartActual
Feb 10, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Apr 2029
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06546085
Responsible party
Steven K Malin, PhD (Associate Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Aug 9, 2024
Start date
Feb 10, 2025
Primary completion
Jan 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jan 23, 2026

Study contacts

Steven K Malin, PhD
Contact
steven.malin@rutgers.edu
848-932-7540
Emily M Heiston, PhD
Contact
emily.heiston@rutgers.edu
848-932-7540
Steven K Malin, PhD
principal investigator · Rutgers University - New Brunswick

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion